Compare Cassava Sciences Inc (FLNA) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while JPMorgan Diversified Return International Eqty ETF trades at $73.01 (market cap $378.77M). The key difference: JPMorgan Diversified Return International Eqty ETF is far larger — about 9.6× Cassava Sciences Inc's market cap, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and JPMorgan Diversified Return International Eqty ETF for 120 Days on average.
| FLNA | JPIN | |
|---|---|---|
Market Cap | $39.40M | $378.77M |
Volume | 759,018 | 13,861 |
Sector | Health | — |
52-Week High | $4.64 | $77.80 |
52-Week Low | $0.68 | $64.96 |
Typical Hold Time | 37 Days | 120 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
JPIN trades at $73.01, up 0.1% on the day, but technical indicators signal a bearish trend with 21 sell signals versus 2 buy signals. The ETF exhibits oversold conditions with RSI readings below 25, while moving averages and ADX reinforce downward momentum. A dividend of $0.51 is scheduled for payment in September 2026, offering income potential amid weak price action.
The outlook remains cautious due to strong bearish technical pressure, though oversold RSI levels may attract contrarian buyers. Risks include persistent selling pressure and reliance on international equity markets. Investment appeal hinges on dividend yield and potential mean reversion if broader market sentiment improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
